Compare Citigroup Inc. (C) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Citigroup (C) trades at $135.22, up 0.17% with bullish technical signals and strong fundamental momentum. The stock shows robust earnings performance with Q1 and Q2 2026 beats, revenue growth to $85.21B in 2025, and improving profit margins. Analyst consensus is strongly bullish with a $154.38 price target, supported by recent strategic hires and digital transformation initiatives.

Outlook remains positive with revenue projected to reach $91.4B in 2026 and net income margin expanding to 19.52%. Key risks include volatile cash flow patterns and high debt levels. The current valuation at 14.63 P/E offers attractive upside potential relative to analyst targets, though investors should monitor execution of the bank's transformation strategy.

ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.

The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.